



The
Inaugural
Meeting
of the
**CORPORATE
HEALTH
ALLIANCE**

Hotel Bethlehem, Pennsylvania





OraSure Technologies, Inc.



Welcome!

On behalf of OraSure Technologies, I want to thank you for joining us for this important meeting of pharmaceutical and diagnostic leaders in viral hepatitis, public health officials on the federal, state and local level and members of select advocacy groups. It is our pleasure to serve as host for this meeting in the city of our corporate headquarters, Bethlehem, Pa.

At OraSure, we recognize that there is a significant change on the horizon with several new Hepatitis therapies in development and the expected introduction of the very first rapid diagnostic test for the screening of Hepatitis C. Our OraQuick® Rapid HCV Test, which is currently under review by the U.S. Food and Drug Administration, will lead to identifying more individuals who are candidates for treatment. Unfortunately, the current healthcare system is inadequate to appropriately diagnose patients and ensure they receive care. We value your commitment to ensuring patients have access to quality care and recognize your leadership in expanding hepatitis diagnosis and treatment.

It is critical that we identify ways in which industry can play a central role in advocating for increased access to viral hepatitis services in the United States. It truly is an honor to welcome you to this important gathering, and I know that through our collective efforts, we will make a significant difference for those at risk for, and infected with viral hepatitis.

Thank you again for your contribution to this effort.

Sincerely,

Douglas A. Michels
President and Chief Executive Officer



August 13, 2009

Dear Advocacy and Industry Partners:



The National Alliance of State and Territorial AIDS Directors (NASTAD) is pleased to join OraSure Technologies, Inc. in welcoming you to this important meeting of hepatitis advocates and industry partners in Bethlehem, Pennsylvania. As you are aware, the nation has been slow to respond to the viral hepatitis epidemics in the United States. Coalitions, individual advocates and the pharmaceutical and diagnostics industries must continue raising the profile of viral hepatitis with the Administration, Members of Congress and other policy makers at the Federal and State levels.

This meeting provides an excellent opportunity for the pharmaceutical and diagnostic industries to strengthen their collective advocacy efforts. With the expertise and resources available to highlight prevention and care needs, private industry plays a critical role in federal advocacy. Working together, industry can develop a collaborative advocacy strategy to increase federal action, including much needed appropriations. At the same time, community coalitions, which include industry, are conducting important advocacy in Washington, DC. We hope that industry will develop a strategy that parallels and complements community advocacy efforts. The partnership between industry and community advocates is essential to more effectively communicate the viral hepatitis advocacy agenda to Federal policymakers.

NASTAD represents the public health officials that administer state and territorial HIV/AIDS and adult viral hepatitis prevention and care programs nationwide. On average, health departments receive \$90,000 to prevent viral hepatitis in their jurisdictions. Without additional federal funding, health departments are not able to provide funding to local health departments and community based organizations to provide core public health services.

We look forward to fruitful discussion over the next day, to the development of a robust industry advocacy strategy, and to strengthened partnerships among all key stakeholders. Thank you for your continued dedication to addressing viral hepatitis needs in the United States.

Sincerely,

A handwritten signature in black ink that reads "Julie M. Scofield". The signature is fluid and cursive.

Julie M. Scofield
Executive Director



Industry Role in Viral Hepatitis Advocacy

DAY I Thursday August 13, 2009

- 3:00 PM** **Check in to Hotel Bethlehem**
437 Main St., Bethlehem, PA 18018
- 3:30 PM – 4:00 PM** **Introduction and Welcome**
- Douglas Michels, President and CEO, OraSure Technologies, and Julie Scofield, Executive Director, NASTAD
– *Overview of Meeting Purpose and Objectives*
- 4:00 PM-5:30 PM** **The Hepatitis Advocacy Movement Perspective**
Moderator: Laura Hanen, Director of Government Relations, NASTAD
- Hepatitis B Community: Joan Block, Executive Director and Co-Founder Hepatitis B Foundation
 - Hepatitis C Advocates UNITED! and National Hepatitis C Advocacy Council:
Lorren Sandt, Co-Founder
 - Hepatitis C Appropriations Partnership: Chris Taylor, Senior Manager, Viral Hepatitis NASTAD
 - National Viral Hepatitis Roundtable: Martha Saly, Director
- 5:30 PM – 6:00 PM** **OraSure Rapid HCV Test Update**
- Stephen R. Lee, Ph.D., Executive Vice President and Chief Science Officer, OraSure Technologies
- 6:00 PM – 7:00 PM** **Reception**
- 7:00 PM – 9:00 PM** **Dinner**
Our Advocacy and Policy Responsibilities
- Larry Lucas, Deputy Vice President, PhRMA

DAY II Friday August 14, 2009

- 8:00 AM – 9:00 AM** **Breakfast**
- 9:00 AM – 9:15 AM** **Welcome**
- Douglas Michels, President and CEO, OraSure Technologies, and Julie Scofield, Executive Director, NASTAD
 - Debra Fraser-Howze, Vice President, Government and External Affairs, OraSure Technologies
– *Purpose of meeting*
- 9:15 AM – 10:45 AM** **Public Health and Primary Care Discussion Perspective**
Moderator: Julie Scofield, Executive Director, NASTAD
- Shannon Hader, MD, MPH, Senior Deputy Director, DC Department of Health
 - Eric Rude, MA, MSW, Director, Office of Viral Hepatitis Coordination at NYC Department of Health and Mental Hygiene
 - Gilbert R. Parks, M.D., General Psychiatry, Mental Health and Hepatitis Treatment
 - Harry L. Simpson, Executive Director and CEO, Point of Change, Inc.
- 10:45 AM – 11:00 AM** **Break**

- 11:00 AM – 11:30 AM Public Health and Hepatitis Prevention Federal Perspective**
- Kevin Fenton, M.D., Ph.D., Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)
- 11:30 AM – 1:00 PM Lunch**
- Increasing Congressional Action on Viral Hepatitis**
- Dale Dirks, President and CEO, Health and Medicine Council of Washington
 - The Honorable Congressman Charles W. Dent
- 1:00 PM – 2:45 PM Industry Role in Hepatitis Advocacy**
- Facilitator: Debra Fraser-Howze, Vice President, Government and External Affairs, OraSure Technologies, and Manuel Mendez, Vice President, Marketing, OraSure Technologies**
- Discussion about the current and future role of industry in advancing hepatitis policy and advocacy. Each company will have the opportunity to share advocacy activities and priorities.
- Questions to Consider*
- What can industry do to strengthen public health infrastructure?
 - What can industry do to enhance screening, care and treatment of persons with viral hepatitis?
 - What role does industry play in the federal advocacy arena?
 - How can industry work collectively (and with advocacy coalitions) to increase the national response to viral hepatitis?
 - Develop timetables and responsibilities across corporations for implementation.
- 2:45 PM – 3:30 PM Closed Sessions**
- Session A: Forming Advocacy Partnerships (Industry Representatives Only)
Session B: Moving Hepatitis Advocacy Forward (Advocacy Representatives Only)
- 3:30 PM – 4:00 PM Reconvene Meeting Participants**
- Facilitator: Laura Knipmeyer, Executive Director, Patient Advocacy – Virology Public Affairs International, Schering-Plough**
- Develop next steps in moving forward to work together*
- 4:00 PM Closing Remarks**
- Douglas Michels, President and CEO, OraSure Technologies, and Julie Scofield, Executive Director, NASTAD
- Meeting ends*



Douglas A. Michels
President and Chief Executive Officer,
OraSure Technologies, Inc.

Douglas A. Michels joined OraSure Technologies, Inc. in June 2004, as President and Chief executive Officer. He is a member of the Board of Directors and an Executive Officer of the Company.

Prior to joining the Company, Mr. Michels spent 19 years at Johnson & Johnson and seven years with Abbott Laboratories. At Johnson & Johnson, he was President, International, for Ortho-Clinical Diagnostics, Inc., and President of Johnson & Johnson Health Care Systems, Inc. He also held numerous General Management and Marketing and Sales positions, in both medical devices and diagnostics. While at Abbott Laboratories, he held various sales and marketing positions. Mr. Michels currently serves on the Board of St. Luke's Hospital and Health Network in Bethlehem, Pa. and has previously served on the Board of the National Blood Foundation, the Board of the National Committee for Quality Health Care, and the Coalition to Protect America's Health Care. Mr. Michels received a B.S. degree in Public Health Administration from the University of Illinois and an MBA from Rutgers University.



Debra Y. Fraser-Howze
Vice President of Government and External Affairs,
OraSure Technologies, Inc.

Debra Y. Fraser-Howze joined OraSure Technologies in January 2008 as Vice President of Government and External Affairs.

In her role, Ms. Fraser-Howze is charged with developing business opportunities in new markets for the Company. She works with lawmakers to implement routine HIV testing and works to ensure laws and resources are available to communities in need of testing. She also develops external opportunities with clients, stakeholders and business partners.

Prior to joining OraSure Technologies, Ms. Fraser-Howze served as the President/CEO of National Black Leadership Commission on AIDS (NBLCA), an organization she founded in 1987. NBLCA conducts policy, research and advocacy on HIV and AIDS to ensure effective participation of its leadership in all policy and resource allocation decisions at the national, state and local levels of communities of African descent nationwide. NBLCA is now the largest Black HIV and AIDS non-profit organization of its kind in America.

Ms. Fraser-Howze has been widely recognized for more than two decades of global leadership to communities of color regarding teenage pregnancy, social welfare, and HIV and AIDS. She advised two U.S. Presidents while serving on the Presidential Advisory Council on HIV/AIDS from 1995-2001. She was the Vice Chair of the HIV Human Services Planning Council in New York City and Chaired the National Institute of Health's Public Education Technology Committee. In 2003, she was appointed to the New York City Commission on AIDS and in 2007 to the New York State Governors Health Advisory Council.

Ms. Fraser-Howze holds a B.A. in Interpersonal Communications from Hunter College and a Master's in Public Administration from Baruch College.




Stephen R. Lee, Ph.D.
Executive Vice President and Chief Science Officer,
OraSure Technologies, Inc.

Stephen R. Lee, Ph.D. joined the Company in September 2005, as Executive Vice President and Chief Science Officer. He is an Executive Officer of the Company.

Dr. Lee brings more than 20 years of experience in the immunodiagnostic industry, primarily with Ortho-Clinical Diagnostics, a Johnson & Johnson company. While at Ortho-Clinical Diagnostics, Dr. Lee served as Vice President, Assay Research & Development, Executive Director, Worldwide Immunodiagnostic Product Development and Director, Infectious Disease Assay Development. Dr. Lee has had responsibility for, or direct involvement in, the development of over 40 major diagnostic assays, in such areas as infectious disease, cardiology, oncology and other conditions. In 1997, Dr. Lee was awarded The Johnson Medal, Johnson & Johnson's highest award for Research and Development. Prior to joining Ortho-Clinical Diagnostics, Dr. Lee worked as a scientist for both Wampole Labs and Immunicon Corporation.

Dr. Lee received his Ph.D. degree in Biochemistry from Cardiff University (UK) and his BSc. in Biochemistry from Sheffield University (UK)



Manuel O. Mendez
Global Vice President Marketing
OraSure Technologies, Inc.

Manuel joined OraSure in 2009 as Global Vice President of Marketing.

Prior to joining OraSure, Mr. Mendez enjoyed a distinguished 18 year career in the medical and scientific fields, and most recently served as the Head of Global Sales, Global Chemicals, BioSciences at Thermo Fisher Scientific, where he was responsible for all sales operations for a \$350 million business unit. Prior to that position, he served as Head of Global Marketing and Business Development at that same company.

Additionally, Manuel spent 16 years with Abbott Laboratories, during which he built a successful career in General Management, Sales, Global Marketing and Business Development in locations ranging from Latin America to North America to Asia and Europe. His experience included service as General Manager in Korea from 2003 to 2005 and General Manager for the Benelux region from 2005 to 2007.

Displaying a wide range of interests, Manuel is actively involved in public service as well as community organizations where he serves or has served in a variety of leadership roles. He currently serves as Board Member of the Jorge Posada Foundation.

Manuel holds a Bachelor of Science (BS) degree in Biomedical Engineering from Boston University and a Master of Business Administration (MBA) degree from Northwestern University Kellogg School of Management. Manuel was born and raised in Puerto Rico, and has lived in numerous countries including Latin America, Korea, Japan, and Belgium.



Joan M. Block, RN, BSN
Executive Director and Co-Founder,
Hepatitis B Foundation

Joan Block is Co-Founder and Executive Director of the Hepatitis B Foundation (HBF), which is a national nonprofit organization dedicated to finding a cure for hepatitis B and improving the lives of those affected worldwide through research, education and patient advocacy.

The Foundation was started in 1991 in response to a young family affected by this serious liver disease. Today, the HBF has grown from a kitchen grassroots efforts into a professional organization with a global reach. It created an 110,000 square foot biotech center that now houses the HBF offices and research institute, which has one of the largest concentrations of hepatitis B scientists in the U.S. working on drug discovery and biomarker discovery for the early detection of cirrhosis and primary liver cancer.

Under Ms. Block's leadership, the HBF coordinates national and international scientific conferences; provides research training programs; offers comprehensive outreach and education programs; maintains a website that attracts 1 million visitors from 180 countries; sponsors a national hepatitis B patient conference; and helps lead national advocacy initiatives that are making an impact.

Ms. Block currently serves on the Board of the Hepatitis B Foundation, Institute for Hepatitis and Virus Research, the Medical Advisory Board of PKIDs, and the Steering Committee of the National Viral Hepatitis Roundtable. She is a member of the National Hepatitis B Task Force: Focus on AAPIs and the Hepatitis B Expert Panel of the Office of Minority Health, and served on the national Board of the American Liver Foundation from 1998-2001. Ms. Block speaks at national conferences, has co-authored published articles, and professional nursing experience in pediatric oncology, adult cardiac care, and nursing education.



Mollie Conti
Associate Director, B-PAL Program,
Bristol-Myers Squibb

Mollie Conti is the current Associate Director of the B-PAL Program at Bristol-Myers Squibb. She has over 10 years of experience as a professional manager. Mollie has the ability to direct projects from concept to fully operational status. She is goal-oriented and possesses strong leadership capabilities. Mollie is highly motivated and a detailed-directed problem solver.

Mollie has a Bachelor of Science degree in Community Development from Penn State University.



Charles Dent
Congressman,
United States House of Representatives

Charlie Dent was first sworn in to the United States House of Representatives in January 2005. He represents Pennsylvania's 15th District, which includes all or parts of Lehigh, Northampton, Montgomery, and Berks counties. Congressman Dent currently serves on three House committees: Homeland Security, Transportation and Infrastructure, and Standards of Official Conduct (Ethics). Within the Homeland Security Committee, he serves as Ranking Member of the Subcommittee on Transportation Security and Infrastructure Protection.

Charlie is a 1978 graduate of William Allen High School. He earned a degree in Foreign Service and International Politics from the Pennsylvania State University in 1982 and a Master's Degree in Public Administration from Lehigh University in 1993.

Before entering public service, Charlie worked as a development officer for Lehigh University, an industrial electronics salesman, and an aide to then-Representative Don Ritter. Charlie served eight years in the Pennsylvania House of Representatives and six years in the State Senate.

In the state legislature, Charlie was Chair of the Senate Urban Affairs Committee and a task force focusing on the state's children and youth placement services.

Now in his third term in Congress, Charlie has developed an expertise in homeland security and transportation issues through his committee assignments in the House. In those areas, he has championed legislation that would: promote the use of the Civil Air Patrol to better secure our borders; develop a comprehensive screening system that will allow border officials to determine that passengers are who they say they are; enhance chemical plant security; expedite and enforce the repatriation of criminal aliens; require notification to Immigration and Customs Enforcement and detention of illegal aliens that are arrested on state felony charges; advance the use of clean energy technology in public transportation applications; and establish reasonable security provisions for large aircraft.

Charlie has also been an advocate on health issues. In 2008, legislation he and his colleague Rep. Mike Doyle (PA-14) introduced to update the Veteran's Health Administration's outdated HIV/AIDS testing policy was signed into law. He has been instrumental in providing federal funding for melanoma research, and a staunch supporter of medical research through the National Institutes of Health (NIH). Charlie has worked closely with the MPS (Mucopolysaccharidoses) community to draw awareness to this devastating genetic lysosomal storage disease, caused by the body's inability to produce specific enzymes, and focus the research that is being conducted. He has also been active in advancing legislation aimed at the prevention and elimination of chronic viral hepatitis. Finally, Charlie is one of the leading voices in Congress for commonsense medical liability reforms that will increase patient safety, improve the quality of care, reduce the incidence of defensive medicine, preserve access to highly-skilled medical professionals, and ensure fair compensation for injured patients.

Charlie has demonstrated leadership in Washington. He is a Co-Chair of the Tuesday Group. In 2005, Charlie joined with three colleagues to form the bi-partisan Hydrogen & Fuel Cell Caucus. Under Charlie's leadership as a Co-Chair, the caucus plays an important role in promoting and enhancing awareness of hydrogen and fuel cell technology. Since the 110th Congress, Charlie has served as the Pennsylvania Co-Chair of the Delaware River Basin Task Force which is a bipartisan group of members of the U.S. House of Representatives from the four basin states (Delaware, New Jersey, New York, and Pennsylvania) that coordinate Congressional efforts to promote the restoration and vitality of the Delaware River Basin and its communities. Representing one of the top cement-producing District in the nation, Charlie also Chairs the Congressional Cement Caucus.



Dale Dirks
President,
Health & Medicine Counsel of Washington

Dale P. Dirks has been the President of the Health and Medicine Counsel of Washington since 1986. The Health and Medicine Counsel of Washington is a government relations firm specializing in the federal budgeting and appropriations process. The Health and Medicine Counsel of Washington specializes in the federal budgeting and appropriations processes and has been working with OraSure Technologies, Inc. since 2006.



Kevin Fenton, MD, PhD
Director, National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention

Kevin Fenton, M.D., Ph.D., FFPH, is the director of the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP). In November 2005, Dr. Fenton was named director of the National Center for HIV, STD, and TB Prevention, which was renamed NCHHSTP in March 2007 to reflect the addition of CDC's Viral Hepatitis program. He previously served as chief of CDC's National Syphilis Elimination Effort since January 2005. He has worked in research, epidemiology, and the prevention of HIV and other STDs since 1995 and was previously the Director of the HIV and STI Department at the United Kingdom's Health Protection Agency.

Dr. Fenton has spearheaded the development of a number of national HIV, STD and behavioral surveillance and research programs in the U.K. and Western Europe including the National Chlamydia Screening Program in England, the 2nd British National Survey of Sexual Attitudes and Lifestyles and the European Surveillance of STI (ESSTI) Network. He is a Fellow of the Faculty of Public Health of the Royal Colleges of Physicians of the United Kingdom.



Shannon L. Hader, MD
Senior Deputy Director,
Government of the District of Columbia, DOH

Dr. Shannon Hader is a public health doctor, with a career focus on HIV/AIDS, building capacity and sustainable systems for quality service delivery, and leveraging of resources and technical supports to strengthen HIV-specific as well as general health outcomes. She is currently the Senior Deputy Director for the District of Columbia Department of Health, HIV/AIDS Administration.

Dr. Hader joined CDC in 1999 as an Epidemic Intelligence Service Officer, and has addressed issues such as emerging epidemics in rural Mississippi and rural Russia, Women and HIV in the United States, adherence and directly observed antiretroviral therapy, and development of HIV treatment programs in resource-poor settings. She's worked clinically caring for children and adults in the United States and abroad, in Brasil, China, Jamaica, and Zimbabwe. She's served as the Director of Centers for Disease Control and Prevention (CDC), Zimbabwe under severe political, economic, and humanitarian conditions. During that time, the US Government HIV Team in Zimbabwe (State Department, USAID, Department of Defence, and CDC) worked in partnership with the Ministry of Health, National AIDS Council, academia, and civil society to reduce the prevalence of HIV among adults (from 25% to 19%), to expand the number of persons tested and receiving care and support for HIV, and to initiate HIV treatment for approximately 40,000 persons. She was detailed to the Department of State as the Senior Scientific Advisor for the President's Emergency Plan for AIDS Relief, during which time she established the public health evaluation infrastructure for the \$15 billion worldwide program, and was instrumental in the planning and implementation of the 2007 HIV Implementers' Meeting—the first worldwide meeting co-sponsored by PEPFAR, Global Fund, World Bank, UNAIDS, UNICEF, WHO, and GNP+ to share best practices on implementation.

Dr. Hader completed her undergraduate degree at Stanford University, medical school at Columbia University, residencies in Internal Medicine and Pediatrics at Duke University, and fellowship in Infectious Diseases at Emory University Hospital. She was also an adjunct clinical faculty at Emory University, and was a 2007 Katherine Hepburn Fellow at Bryn Mawr College.



Laura Hanen
Director of Government Relations,
National Alliance of State & Territorial AIDS Directors

Laura Hanen has been the Director of Government Relations for the National Alliance of State and Territorial AIDS Directors (NASTAD) for the last nine years. NASTAD represents the chief HIV/AIDS program administrators who are responsible for managing federally and state-funded HIV/AIDS and viral hepatitis prevention, care and treatment services in every state and territory. Ms. Hanen's primary responsibility is to oversee the policy development and federal lobbying on appropriations and legislation related to HIV/AIDS and viral hepatitis prevention, care and treatment issues. Ms. Hanen has leadership roles in a number of national coalitions including the Federal AIDS Policy Partnership, the HIV Health Care Access Working Group, the ADAP Working Group, and the Hepatitis C Appropriations Partnership. Ms. Hanen joined NASTAD in May 2000.

Prior to coming to NASTAD, Ms Hanen was the Senior Lobbyist for the American College of Obstetricians and Gynecologists for 3 years. Ms. Hanen was a legislative assistant for Congressman Rick Boucher of the Ninth District of Virginia. Ms Hanen was also a legislative assistant in the Government Relations Department of the Biotechnology Industry Organization.

Ms. Hanen received her Bachelor's degree from Earlham College in Richmond, Indiana and a Master's degree in Public Policy from Georgetown University in Washington, D.C.



Laura Knipmeyer, Ph.D.
Executive Director, Patient Advocacy, Virology, Public Affairs International,
Schering-Plough

Laura Knipmeyer, Ph.D. was appointed Executive Director, Patient Advocacy, Virology, in October 2006. In this new position in the Public Affairs International group, Dr. Knipmeyer is responsible for the Company's relationships with HIV, hepatitis and drug dependence patient advocacy groups, as well as with professional, government and non-governmental organizations. The position was created to develop the Company's focus on patients in the Virology area.

Dr. Knipmeyer joined Schering-Plough in September 2004 as senior project leader for the CCR5 receptor antagonist vicriviroc, which is currently in clinical development for the treatment of HIV. Prior to Schering-Plough, she held global project leader roles at Sandoz Pharmaceuticals, Novartis and Elusys Therapeutics, Inc.

Dr. Knipmeyer holds a Ph.D. in organic chemistry from the University of California at Berkeley and a Bachelors degree in chemistry from Northeastern University.



William (Larry) Lucas
Vice President, Government Affairs/Diversity Programs,
Pharmaceutical Research and Manufacturers of America

Larry Lucas serves as Vice President, Government Affairs/Diversity Programs for the Pharmaceutical Research and Manufacturers of America (PhRMA) where he works with the U.S. Congress and state legislators on issues impacting patient's access to medicines, access to quality health care and the research-based pharmaceutical industry.

At PhRMA, Lucas leads the association's efforts to work with patients, healthcare providers, physicians, legislators and health organizations and educate them on the issues impacting the minority community and their access to quality health care. Lucas also writes a nationally syndicated monthly column about new developments in the pharmaceutical industry.

Lucas is on the Board of Trustees for the National Association for the Advancement of Colored People (NAACP), and also is actively involved in their contribution fund and health committee. Lucas serves on the Corporate Advisory Council to the National Hispanic Medical Foundation; on the Board of Directors, Congressional Black Caucus Institute and was recently appointed to the Africa Diaspora North Initiative Strategic Planning Committee Board.

Lucas received his B.S. degree in Education from Jackson State University in Mississippi and served in the United States Air Force.



Emily Oster
Health Policy Analyst, Government Affairs & Policy,
Vertex Pharmaceuticals, Inc.

Emily Oster joined Vertex's Government Affairs and Public Policy department in July 2008 as a health policy analyst where she focuses on hepatitis C policy issues. Prior to joining Vertex, Emily worked at the Biotechnology Industry Organization (BIO) in the policy department. She earned her MPH from Johns Hopkins Bloomberg School of Public Health and her BA from Muhlenberg College.



Chris Platanos
Director, Sales Training and Market Development,
Three Rivers Pharmaceuticals, LLC

As the Director of Sales Training & Market Development for Three Rivers Pharmaceuticals, Chris has been involved in the Hepatitis C arena the past 6 years. Chris started his career at Wyeth Biopharma in the immunology division in sales. Chris has excelled in pharmaceutical sales winning multiple President Club awards as a Clinical Sales Specialist and as a Regional Director. Before he started his pharmaceutical career, Chris was a high school teacher and soccer coach. Chris has a Bachelor of Arts degree in Business Administration and Marketing from Grove City College and a Master's in Education from Indiana University.



Gilbert R. Parks, M.D.
General Psychiatry

Gilbert R. Parks is a graduate of the University of Central Oklahoma and Thomas Jefferson medical school. He attended the Menninger School of Psychiatry. Dr. Parks is licensed in Kansas and Oklahoma and has engaged in a private practice of psychiatry for more than 33 years. He has concentrated his practice on the delivery of services to a wide range of individuals, which include the treatment of substance abuse. He has focused on providing service to the chronically mentally ill, veterans, the African-American population in general, and African-American men in particular. He also has focused many years of his work on the affects of infectious diseases and has lectured widely on the affects of HIV/AIDS and Hepatitis C virus on the African-American population. Dr. Parks has also held distinguished positions and has received numerous awards throughout his career, including the Haitian government's outstanding service award for service to the Haitian people from President Aristide.

Eric J. Rude, MSW
Director, Office of Viral Hepatitis Coordination – City Research Scientist II,
New York City Department of Health and Mental Hygiene

As New York City's Viral Hepatitis Prevention Coordinator, Eric Rude runs the Office of Viral Hepatitis Coordination within the Division of Disease Control. To control the spread of viral hepatitis in New York City he employs a three-pronged strategy: training health professionals and educating the public, identifying people exposed to hepatitis B and C, and locating and enhancing referral resources for follow-up medical care. Eric received his Master of Social Work degree at the University of Denver in Colorado and his undergraduate degree at the University of Vermont. His career in health care and infectious disease prevention has spanned over 20 years and includes employment with various community-based organizations and government agencies.

Martha Saly
Director
National Viral Hepatitis Roundtable

Martha Saly is the Director of the National Viral Hepatitis Roundtable (NVHR), a coalition of public, private, and voluntary organizations dedicated to reducing the incidence of infection, morbidity, and mortality from viral hepatitis in the United States. Martha oversees NVHR's general operations and represents NVHR in a cooperative agreement with the Centers for Disease Control, administered by NASTAD. Under this agreement, NVHR works to improve linkages and collaboration between viral hepatitis organizations around the nation.

Martha is the senior consultant to the California Hepatitis Alliance (CalHEP), a statewide coalition formed to improve California's approach to viral hepatitis through sound public health policy. CalHEP is a program of the Center for Health Improvement in Sacramento, California, which has served as a home to several hepatitis programs that Martha developed from 2002 to 2008. These included a collaborative of 12 rural county health departments to address hepatitis C; a telemedicine hepatitis education program between UC Davis Medical Center and the Hoopa Indian Reservation; a collaborative of methadone clinics organized to improve hepatitis services for methadone clients; two syringe access policy projects, and the California Hepatitis Alliance.

Martha has been a consultant specializing in inter-organizational collaboration since 1997. She holds a Masters degree in Organization Development from the University of San Francisco (USF) and was formerly on the faculties of USF and Saint Mary's College of California.

Following her successful treatment for hepatitis C in 2000, Martha dedicated herself to working to improve access to education and care for persons who did not have the same access and resources that she when she sought care and treatment for her disease. Martha lives in Rohnert Park, California with her husband David.




Lorren Dietrich Sandt
Executive Director,
Caring Ambassadors Program

Ms. Sandt is the co-founder and Executive Director of the Caring Ambassadors Program. She has managed the Hepatitis C Program of the Caring Ambassadors Program since its inception in 1999. Lorren is a co-editor and a contributing author, to *Hepatitis C Choices*, 4th Edition, a one-of-a-kind, patient-centered book authored by a team of more than 25 multi-disciplined experts in hepatitis C. She has worked on policy changes at both the state and federal level since 2001. Lorren is the founder and past President of the National Hepatitis C Advocacy Council, the vice-chair of the National Viral Hepatitis Roundtable, co-moderator of Hepatitis C Advocates UNITED, and a member of the Hepatitis C Appropriations Partnership.



Harry L. Simpson
Executive Director/CEO
Point of Change, Inc.

Mr. Simpson is the Founder and Executive Director of Point of Change, Inc., a leading Detroit-based ASO. Mr. Simpson has served as a contributor to the NIDA publication *Principles of HIV Prevention in Drug-Using Populations: A Research-Based Guide*, was selected to receive the CDC Price Fellowship to study the role of sterile injection equipment in the prevention of HIV transmission, was Join Together Fellow at Boston University in 1997 and completed the Executive Program in Public Management at Harvard University, John F. Kennedy School of Government. More recently, Mr. Simpson was appointed to Michigan Governor Jennifer Granholm's Hepatitis C Task Force where he chair's the Syringe Access Workgroup.



Julie M. Scofield
Executive Director,
National Alliance of State & Territorial AIDS Directors

National Alliance of State & Territorial AIDS Directors Julie Scofield joined the National Alliance of State and Territorial AIDS Directors (NASTAD) as their first Executive Director in February 1993. Under Ms. Scofield's leadership, NASTAD has grown from a staff of one, to a highly respected national HIV/AIDS and viral hepatitis organization of over 50 professionals and major programs in the areas of prevention and surveillance, care and treatment, racial and ethnic health disparities, viral hepatitis, government relations, and global HIV/AIDS technical assistance. Prior to opening NASTAD's national office, Ms. Scofield served as legislative assistant in the State of New York Office of Federal Affairs. Ms. Scofield represented the state on science and technology and health issues including HIV/AIDS policy and funding before Congress and the Administration from 1987 to 1993. Scofield served on the legislative staff of former U.S. Representative Stan Lundine from 1981 to 1987. Scofield is a graduate of Buffalo State College.



Willis Steele, M.Div.
Area Community Affairs Manager Virology
Abbott Laboratories, Inc.


Rev. Willis Steele holds a Master of Professional Studies in Urban Ministry and earned his Master of Divinity in May 2002 from N Y Theological Seminary. He is a member of the Abyssinian Baptist Church under the leadership of the Rev. Dr. Calvin O. Butts, III, where was ordained to the Gospel Ministry. He is currently co-pastor of Faith Mission, Grace Baptist Church Yonkers, with his wife Rev. Gay Tompson Steele, and serves Young Adults, Couples, and Singles ministries at Grace Baptist Church in Mt. Vernon. Rev. Steele is an Area Community Affairs Manager, for Abbott Laboratories where he helps them navigate through unchartered waters in an effort to empower the disenfranchised suffering with HIV/AIDS in our faith communities even as he otherwise works closely with Hospitals, Clinics, CBOs and AIDS Service Organizations. He educates patients living with this challenging illness, as well as support staff to primary providers who treat and service they and their families. families. . At the Bronx Lebanon Hospital Center, Rev. Steele was the developed and Managed a dynamic Treatment Education Program in the Department of Medicine & Infectious Diseases. Rev Steele serves on the Boards of the Magic Johnson Foundation, Gospel Heritage Foundation, and the Memorial Community Services. And Harlem project that houses formerly homeless single parents.



Chris Taylor
Senior Manager, Viral Hepatitis,
National Alliance of State & Territorial AIDS Directors

Chris Taylor is the Senior Manager, Viral Hepatitis for the National Alliance of State and Territorial AIDS Directors (NASTAD). In this role, he provides support and technical assistance to state health department viral hepatitis programs, advocates on their behalf with the Administration, Congress and Federal agencies. He is actively involved in several national hepatitis advocacy coalitions, provides leadership as chair of the National Viral Hepatitis Roundtable, and is the North American delegate to the World Hepatitis Alliance. Mr. Taylor has 14 years of experience working in public health on viral hepatitis, HIV, STD, tuberculosis and immunization at the local state and national level.





C O R P O R A T E H E P A T I T I S A L L I A N C E

➤ Working together to lead the way in diagnosis and care



OraSure Technologies, Inc.

220 East First Street, Bethlehem, PA 18015-1360 • Phone: 610.882.1820 • Fax: 610.882.1825 • www.orasure.com